📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Eisai Co Ltd

Common Name
Eisai
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
10,917
Ticker
4523
Exchange
TOKYO STOCK EXCHANGE
Description
Eisai Co., Ltd. is a major pharmaceutical company specializing in the research, development, and manufacture of innovative pharmaceuticals. Its primary function is to deliver prescription drugs and th...

Eisai's Financial Statements Preview

Below are the financial statements of Eisai, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in billions of JPY
2023
2022
2021
2020
2019
Revenue
741.8a
744.4a
756.2a
645.9a
695.6a
Cost of sales
-155.3a
-177.8a
-174.8a
-161.3a
-175.7a
Gross profit
586.4a
566.6a
581.4a
484.6a
519.9a
Research and development expenses
-169a
-173a
-171.7a
-150.3a
-140.1a
Selling, general and administrative expenses
-374.4a
-358.3a
-366.4a
-281.6a
-256.3a
Other income
12a
8.3a
14.6a
1.5a
6.4a
Other expenses
-1.6a
-3.5a
-4.1a
-2.6a
-4.4a
Operating profit
53.4a
40a
53.7a
51.5a
125.5a
Profit for the year
43.8a
56.8a
45.7a
42.3a
122.5a
Profit for the year attributable to owners of the parent
42.4a
55.4a
48a
41.9a
121.8a
Download Data

Verified Sources Behind Eisai’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Eisai’s data sources below and access millions more through our Disclosure Search.

a. Eisai's Integrated Report 2024
a. Eisai's Integrated Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?